R&D channel feed

Crushed by a PhI­II flop, No­vavax slash­es jobs as it looks to chop out up to $100M in costs

9 years ago

Cel­gene EVP Rich Bag­ger makes Politi­co’s short list for Trump’s Cab­i­net

9 years ago

Kite gives it­self a lit­tle more time to fin­ish FDA ap­pli­ca­tion for KTE-C19

9 years ago
Pharma

As elec­tion storm gath­ered, Ar­row­head drops word about a clin­i­cal hold

9 years ago

Cure­Vac grabs a $29.5M round to fu­el its mR­NA de­vel­op­ment ef­forts

9 years ago

Ver­sant’s glob­al biotech team is re­load­ing with $350M-plus fund

9 years ago

Car­dio event forces FDA to halt a Penn PhII study for mul­ti­ple myelo­ma

9 years ago

Car­dio drug at The Med­i­cines Co gets the heave-ho. (But they pre­fer PC­SK9 any­way.)

9 years ago

Roche flags ear­ly suc­cess for Tecen­triq com­bos, hus­tles in­to PhI­I­Is

9 years ago

Poised to launch a new drug for SMA, Bio­gen and Io­n­is shares jump on more promis­ing PhI­II da­ta

9 years ago

Sanofi jumps in­to a piv­otal study for next-gen Pompe drug

9 years ago

Nestlé in­vests $145M in Aim­mune’s food al­ler­gy R&D work, tak­ing the head seat at the deal ta­ble

9 years ago

Celyad chief blasts Cel­lec­tis’ CEO Chouli­ka, claim­ing he lied about CAR-T patent

9 years ago

The losers are pil­ing up af­ter to­day’s big ASH ab­stract drop

9 years ago

Spark Ther­a­peu­tics shares slide af­ter a set­back on its he­mo­phil­ia gene ther­a­py study

9 years ago

In­ves­ti­ga­tors sound a safe­ty alarm af­ter 2 pa­tients die of heart con­di­tion fol­low­ing check­point com­bo

9 years ago

Mer­ck can’t prove its Alzheimer’s drug works, yet, but it did just ex­plain why it’s spend­ing a for­tune on PhI­II

9 years ago

Se­vere ad­verse events mar the end of Roche’s PhI­II for ‘break­through’ he­mo­phil­ia drug

9 years ago

PTC sees high­er reg­u­la­to­ry risk in fight to keep its Duchenne drug on the Eu­ro­pean mar­ket

9 years ago

Buf­fet­ed by safe­ty fears, Cem­pra shares crushed af­ter FDA flags a warn­ing on its an­tibi­ot­ic

9 years ago

On­colyt­ic con­tender Turn­stone bags a $41M B round to push a suc­ces­sor for Im­ly­g­ic

9 years ago

Still pon­der­ing an M&A move, Gilead­'s R&D team out­lines a Q3 line­up of set­backs on 3 pipeline drugs

9 years ago

AveX­is shares soar af­ter it out­lines FDA’s sup­port for a loom­ing piv­otal study on SMA

9 years ago

Post-PhI­II im­plo­sion, Celldex buys on­col­o­gy drug de­vel­op­er Koll­tan in $235M deal

9 years ago
First page Previous page 313314315316317318319 Next page Last page
A service from the Financial Times